HomeMarketsEarningsLLY Tops Earnings, Stock Sheds Weight on Disappointing GLP-1 Pill Trial

LLY Tops Earnings, Stock Sheds Weight on Disappointing GLP-1 Pill Trial

Eli Lilly (LLY) shares dropped after its latest earnings report and disappointing results for an oral GLP-1 pill. Lee Brown joins Sam Vadas to discuss the phase 3 trial and says "the markets missing the big picture here" believing "tolerability" is the key focal point. He points to the differences in Novo Nordisk (NVO) and LLY weight-loss drug offerings. Lee dives into Mounjaro's cardio-protective results as well, saying it might be "overlooked" in today's report.

Morning Movers

07 Aug 2025

SHARE

ON AIR
education
2:00 am
Your First Trade
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
ON AIR
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor